Related references
Note: Only part of the references are listed.Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors
W. T. Lim et al.
ANNALS OF ONCOLOGY (2010)
nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study
Mikhail Y. Biakhov et al.
EXPERT OPINION ON DRUG SAFETY (2010)
Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
Kazuhiko Yamada et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients
Juergen B. Bulitta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients
Juergen B. Bulitta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
Neil Desai et al.
TRANSLATIONAL ONCOLOGY (2009)
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel
Gerald J. Fetterly et al.
CLINICAL CANCER RESEARCH (2008)
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
Erin R. Gardner et al.
CLINICAL CANCER RESEARCH (2008)
Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL(R)-free formulation of paclitaxel
Thomas E. Stinchcombe
NANOMEDICINE (2007)
Albumin-bound paclitaxel - In metastatic breast cancer
Dean M. Robinson et al.
DRUGS (2006)
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies
DW Nyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
A Sparreboom et al.
CLINICAL CANCER RESEARCH (2005)
Development and characterization of a novel Cremophor (R) EL free liposome-based paclitaxel (LEP-ETU) formulation
JA Zhang et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2005)
Tocol emulsions for drug solubilization and parenteral delivery
PP Constantinides et al.
ADVANCED DRUG DELIVERY REVIEWS (2004)
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients
A Henningsson et al.
EUROPEAN JOURNAL OF CANCER (2003)
Pharmacological effects of formulation vehicles - Implications for cancer chemotherapy
AJ ten Tije et al.
CLINICAL PHARMACOKINETICS (2003)
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
LE Friberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling
HJGD van den Bongard et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition
DE Mager et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2001)
Mechanism-based pharmacokinetic model for paclitaxel
A Henningsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
High affinity binding of paclitaxel to human serum albumin
K Paál et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients
L van Zuylen et al.
ANTI-CANCER DRUGS (2000)
Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel
PP Constantinides et al.
PHARMACEUTICAL RESEARCH (2000)
Share Paper
